Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Immune Pharmaceuticals Inc EPCTD


Primary Symbol: IMNPQ

Healthcare Biotechnology
Immune Pharmaceuticals Inc is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead program, bertilimumab is a first-in-class, human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of inflammation. By blocking eotaxin-1, bertilimumab may prevent the migration and activation of eosinophils and other cells, blocking inflammatory pathway active in a variety of allergic and immune diseases. Bertilimumab has shown promising clinical activity in bullous pemphigoid and has been studied in other conditions including allergic rhinitis and ulcerative colitis and may have application in other diseases, including atopic dermatitis, asthma, and other diseases.


EXPM:IMNPQ - Post by User

Immune Pharmaceuticals Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by Vacc77on Sep 26, 2016 6:50pm
226 Views
Post# 25279948

Let try at .28

Let try at .28Nice volume last days
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities